Evotec Invests in Oxford University Spinout Cell Therapy Company OxVax
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) revealed that it has invested in OxVax, a new immuno-oncology organization
Read moreEvotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) revealed that it has invested in OxVax, a new immuno-oncology organization
Read moreBristol-Myers Squibb is investing in a brand new cell therapy facility which will be located at the Leiden Bio Science
Read moreIrish pharmaceutical company Shorla Pharma Limited (‘Shorla’), has reported that it has successfully filed a priority review application for its
Read moreHistoSure, in cooperation with Charles River Discovery Research Services Germany, now offers a set of groundbreaking highly validated species-specific antibodies
Read moreThe European Commission (EC) has approved Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult
Read moreEctica Technologies is delighted to announce it will be presenting as a corporate sponsor at the upcoming CHI Conference on
Read moreFrench pharma giant Sanofi is set to acquire Tidal Therapeutics for $470m, adding the biotech’s novel mRNA-based research platform with
Read moreBristol Myers Squibb announced positive results from a Phase 3 Trial, which showed that neoadjuvant treatment with three cycles of
Read moreExscientia, a leading artificial intelligence (AI) driven pharmatech company based in Oxford, England, announced that the first AI-designed molecule for
Read moreThe National Institute for Health and Care Excellence (NICE) has recommended carfilzomib in combination with lenalidomide and dexamethasone (KRd) for
Read more